My studies - Head and Neck

Question 1

MOG/population - KEYNOTE-630

Answer 1

H&N: locally advanced cutaneous SCC

Question 2

IP/sponsor - KEYNOTE-630

Answer 2

Merck, adjuvant pembro (placebo controlled)

Question 3

CRS notable hx - KEYNOTE-630

Answer 3

was Mimi’s study, open since 2019

Question 4

unusual trial features (or new to me) - KEYNOTE 630

Answer 4

“placebo supplied by site”

Question 5

treatment/cycle, dosing - KEYNOTE 630

Answer 5

infusion Q6W for up to 9 weeks

Question 6

MOG/population - ICAGN 2385-203

Answer 6

H&N: recurrent/met SCC of head and neck (not nasopharynx/sinus)

Question 7

IP/Sponsor - ICAGN 2385-203

Answer 7

Incyte, Retifanlimab, ICAGN2385, ICAGN2390

Question 8

CRS notable Hx - ICAGN2385-203

Answer 8

SIV just prior to my arrival, site activated same week I arrived

Question 9

unusual trial features (or new to me) - ICAGN2385-203

Answer 9

2 placebos (2 arms - SOC only, retifanlimab & drug combo or placebo pair added)

Question 10

treatment/cycle, dosing - ICAGN2385-203

Answer 10

Infusions Q4W retifanlimab, Q2W placebo/IP combo. Up to how long???